Document is current

Article History

Received: 27 June 2025

Accepted: 11 February 2026

First Online: 6 April 2026

Change Date: 13 April 2026

Change Type: Update

Change Details: In the version of this article initially published, Joan Bladé (Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Cl.nic de Barcelona, IDIBAPS, and PETHEMA/GEM, Barcelona, Spain) was listed with an incorrect affiliation which is now amended in the HTML and PDF versions of the article.

Competing interests

: The authors report the following competing interests. F.G. reported receiving honoraria from Amgen, Janssen, Takeda, Sanofi, Bristol Myers Squibb/Celgene, AbbVie, Pfizer and GlaxoSmithKline and serving on the advisory boards for Amgen, Janssen, Takeda, Pfizer, Sanofi, Bristol Myers Squibb/Celgene, Oncopeptides, Roche, AbbVie, GlaxoSmithKline, AstraZeneca, Regeneron and Gilead/Kite. W.R. reported receiving (not personal) honoraria from Janssen, Bristol Myers Squibb/Celgene and Genzyme and receiving contributions for travel and accommodation expenses from Janssen and AbbVie. M.A.D. reported receiving honoraria for participation in advisory boards and satellite symposia from Amgen, Sanofi, Regeneron, Menarini, Takeda, GlaxoSmithKline, Bristol Myers Squibb, Janssen, BeiGene, Swixx and AstraZeneca. L.R. reported receiving honoraria for lectures and participation in advisory boards from Janssen, Bristol Myers Squibb, Amgen, Sanofi, GlaxoSmithKline and Menarini. R.M. reported receiving honoraria from Janssen, Pfizer, Sanofi, AbbVie, Regeneron, Bristol Myers Squibb, Takeda and Amgen; serving on the advisory boards for Janssen, Pfizer, Sanofi, Takeda, Bristol Myers Squibb and Amgen; and receiving consultancy fees from Janssen, Pfizer and Sanofi. A.O. reported receiving honoraria for participation in advisory boards and sponsored symposiums from Sanofi, Janssen, Bristol Myers Squibb, GlaxoSmithKline, Pfizer and Amgen. E.K. reported receiving honoraria from and serving on the advisory boards for Janssen, GlaxoSmithKline, Sanofi, Takeda, Amgen, Pfizer and AbbVie and receiving contributions to clinical research from Janssen, Karyopharm, AbbVie, Sanofi, GlaxoSmithKline, Amgen, Pfizer and Prothena Biosciences. K.L.W. reported receiving consultancy fees from Janssen, Takeda and Sanofi. P.R.O. reported receiving honoraria from Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Regeneron, Sanofi and AbbVie; serving on the advisory boards for Janssen, Oncopeptides, H3Biomedicina, GlaxoSmithKline, Pfizer, Sanofi, Bristol Myers Squibb, Roche and Regeneron; receiving consultancy fees from Roche, Pfizer, AbbVie and Bristol Myers Squibb; and being a member of steering committees for Regeneron, Janssen and Bristol Myers Squibb. R.H. reported having a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, Bristol Myers Squibb, Novartis, PharmaMar and Takeda; receiving honoraria from Janssen, Amgen, Celgene, Bristol Myers Squibb, PharmaMar and Takeda; receiving research funding from Janssen, Amgen, Celgene, Bristol Myers Squibb, Novartis and Takeda; serving on the advisory boards for Bristol Myers Squibb, Takeda, Amgen, Oncopeptides, Sanofi, Janssen and GlaxoSmithKline; and receiving support for attending meetings and/or travel from Amgen, Celgene, Takeda and Janssen. E.A. reported receiving honoraria from Sanofi and serving on the advisory boards for Janssen, Takeda, Amgen, Pfizer, Menarini and GlaxoSmithKline. M.D. reported receiving honoraria from GlaxoSmithKline, Sanofi and Janssen; serving on the advisory boards for GlaxoSmithKline, Sanofi, Bristol Myers Squibb, Janssen and Adaptive Biotechnologies; and receiving research support from Janssen. J.M.-L. reported serving on the advisory boards for Sanofi, Janssen, Bristol Myers Squibb, Amgen, Kite and Roche. E.Z. reported receiving honoraria from and serving on the advisory boards for Bristol Myers Squibb, Janssen, Amgen, Pfizer, Oncopeptides, Menarini-Stemline and Sanofi. N.W.C.J.v.D.D. reported receiving research support from Janssen Pharmaceuticals, Amgen, Celgene, CellCentric, Novartis, Cellectis and Bristol Myers Squibb and serving on the advisory boards for Janssen Pharmaceuticals, Amgen, Celgene, Bristol Myers Squibb, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive Biotechnologies, Galapagos, Kite Pharma, Merck, Pfizer, AbbVie and Servier, all paid to the institution. K.C.W. reported receiving research grants to her institution from AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen and Sanofi; receiving research grants from Pfizer and Takeda; receiving honoraria from AbbVie, Amgen, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline and Takeda; and serving on the advisory boards for AbbVie, Amgen, Adaptive Biotechnologies, BeiGene, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi and Takeda. J.R. reported receiving honoraria from and serving on the advisory boards for Johnson & Johnson, Sanofi, Amgen, Pfizer, Bristol Myers Squibb, Janssen, Sanofi and GlaxoSmithKline; and receiving travel reimbursements from Johnson & Johnson and Sanofi. A. Belotti reported serving on the advisory boards for Amgen, Pfizer, Janssen, GlaxoSmithKline and Menarini Stemline. F.S. reported receiving honoraria from Amgen, Bristol Myers Squibb, Takeda, AbbVie, Janssen, Oncopeptides, Sanofi, GlaxoSmithKline, Menarini and Regeneron and serving on the advisory boards for AbbVie, Bristol Myers Squibb, Oncopeptides, GlaxoSmithKline, Janssen, Sanofi and Takeda. J.B. reported receiving honoraria for lectures from Janssen, Amgen, Celgene/Bristol Myers Squibb and Sanofi. H.E. reported having a consulting or advisory role for Bristol Myers Squibb/Celgene, Janssen, Amgen, Takeda, Sanofi, GlaxoSmithKline, Novartis and Roche; receiving research funding from Bristol Myers Squibb/Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi and Novartis; receiving honoraria from Bristol Myers Squibb/Celgene, Janssen, Amgen, Takeda, Sanofi, GlaxoSmithKline, Novartis and Roche; and receiving travel support from Bristol Myers Squibb/Celgene, Janssen, Amgen and Sanofi. P.S. reported receiving research funding from Amgen, Bristol Myers Squibb, Celgene, Janssen and Karyopharm and serving on the advisory boards for Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm and Pfizer. M.B. reported receiving honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb and AbbVie; serving on the advisory boards for Janssen and GlaxoSmithKline and receiving research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb and Mundipharma. A. Broijl reported receiving honoraria from and serving on the advisory boards for Janssen, Sanofi, Bristol Myers Squibb and Amgen. The other authors declare no competing interests.